Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (отвара нови прозор)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Извор‎: Cancer 2013;119(21):3784-7.

Индекс‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (отвара нови прозор)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (отвара нови прозор)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Извор‎: Lancet 1989;334(8655):122-4.

Индекс‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (отвара нови прозор)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (отвара нови прозор)

Ben-Bassat I, Douer D, Ramot B.

Извор‎: Eur J Haematol 1990;45(2):86-9.

Индекс‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (отвара нови прозор)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (отвара нови прозор)

Dean A, Tuffin P.

Извор‎: J Pain Symptom Manage 1997;13(1):20-4.

Индекс‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (отвара нови прозор)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (отвара нови прозор)

Ford PA, Grant SJ, Mick R, Keck G.

Извор‎: J Clin Oncol 2015;33(15):1674-9.

Индекс‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (отвара нови прозор)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (отвара нови прозор)

Garewal HS, Durie BG.

Извор‎: Scand J Haematol 1985;35(5):497-500.

Индекс‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (отвара нови прозор)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (отвара нови прозор)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Извор‎: Cancer 2006;107(1):136-40.

Индекс‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (отвара нови прозор)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (отвара нови прозор)

Marshall A, Li A, Drucker A, Dzik W.

Извор‎: Hematol Oncol 2016;34(3):147-53.

Индекс‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (отвара нови прозор)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (отвара нови прозор)

Prokopchuk-Gauk O, Brose K.

Извор‎: Cureus 2015;7(12):e428.

Индекс‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (отвара нови прозор)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (отвара нови прозор)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Извор‎: Leuk Lymphoma 1995;19(1-2):141-4.

Индекс‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (отвара нови прозор)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (отвара нови прозор)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Извор‎: Hematol Oncol 2008;26(4):241-6.

Индекс‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (отвара нови прозор)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (отвара нови прозор)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Извор‎: Am J Hematol 2006;81(9):720.

Индекс‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (отвара нови прозор)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (отвара нови прозор)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Извор‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Индекс‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (отвара нови прозор)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (отвара нови прозор)

Erduran E, Bahadir A, Mutlu M.

Извор‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Индекс‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (отвара нови прозор)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (отвара нови прозор)

Franchini M, Veneri D, Lippi G.

Извор‎: Bone Marrow Transplant 2007;39(12):729-35.

Индекс‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (отвара нови прозор)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (отвара нови прозор)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Извор‎: Am J Hematol 2002;69(3):219-22.

Индекс‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (отвара нови прозор)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (отвара нови прозор)

Hsieh A, Cheong I.

Извор‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Индекс‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (отвара нови прозор)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (отвара нови прозор)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Извор‎: Haemostasis 1996;26 Suppl 1:159-64.

Индекс‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (отвара нови прозор)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (отвара нови прозор)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Извор‎: Med Oncol 2010;27(1):16-9.

Индекс‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (отвара нови прозор)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (отвара нови прозор)

Vidarsson B, Önundarson PT.

Извор‎: Thromb Haemost 2000;83(4):634-5.

Индекс‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (отвара нови прозор)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (отвара нови прозор)

Zver S, Andoljšek D, Černelč P.

Извор‎: Eur J Haematol 2004;72(6):455-6.

Индекс‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (отвара нови прозор)

Management of bleeding complications of hematologic malignancies. (отвара нови прозор)

Green D.

Извор‎: Semin Thromb Hemost 2007;33(4):427-34.

Индекс‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (отвара нови прозор)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (отвара нови прозор)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Извор‎: Int J Lab Hematol 2013;35(4):457-9.

Индекс‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (отвара нови прозор)

Management of bleeding in patients with advanced cancer. (отвара нови прозор)

Pereira J, Phan T.

Извор‎: Oncologist 2004;9(5):561-70.

Индекс‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (отвара нови прозор)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (отвара нови прозор)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Извор‎: Haematologica 1997;82(5):584-7.

Индекс‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (отвара нови прозор)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (отвара нови прозор)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Извор‎: Bull Cancer 2006;93(2):E7-12.

Индекс‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (отвара нови прозор)